BRD4 Antibody Polyclonal

<strong>BRD4 Antibody Polyclonal</strong>_x000D_ <strong>Catalog number:</strong> B2016858_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 µL_x000D_ <strong>Molecular Weight or Concentration:</strong> 180 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20¬∞C_x000D_ <strong>Keywords:</strong> CAP, MCAP, HUNK1, HUNKI_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Maneiro MA, Forte N, Shchepinova MM, Kounde CS, Chudasama V, Baker JR, Tate EW. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4 ACS Chem Biol. 2020 Jun 19;15(6):1306-1312._x000D_ 2: Wang J, Xu Y, Rao X, Zhang R, Tang J, Zhang D, Jie X, Zhu K, Wang X, Xu Y, Zhang S, Dong X, Zhang T, Yang K, Xu S, Meng R, Wu G. BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer Clin Transl Med. 2022 Jan;12(1):e718._x000D_ 3: Hu Z, Crews CM. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic Chembiochem. 2022 Jan 19;23(2):e202100270._x000D_ 4: Pillow TH, Adhikari P, Blake RA, Chen J, Del Rosario G, Deshmukh G, Figueroa I, Gascoigne KE, Kamath AV, Kaufman S, Kleinheinz T, Kozak KR, Latifi B, Leipold DD, Sing Li C, Li R, Mulvihill MM, O'Donohue A, Rowntree RK, Sadowsky JD, Wai J, Wang X, Wu C, Xu Z, Yao H, Yu SF, Zhang D, Zang R, Zhang H, Zhou H, Zhu X, Dragovich PS. Antibody Conjugation of a Chimeric BET Degrader Enables in‚ÄÖvivo Activity ChemMedChem. 2020 Jan 7;15(1):17-25._x000D_ 5: Dragovich PS, Pillow TH, Blake RA, Sadowsky JD, Adaligil E, Adhikari P, Chen J, Corr N, Dela Cruz-Chuh J, Del Rosario G, Fullerton A, Hartman SJ, Jiang F, Kaufman S, Kleinheinz T, Kozak KR, Liu L, Lu Y, Mulvihill MM, Murray JM, O'Donohue A, Rowntree RK, Sawyer WS, Staben LR, Wai J, Wang J, Wei B, Wei W, Xu Z, Yao H, Yu SF, Zhang D, Zhang H, Zhang S, Zhao Y, Zhou H, Zhu X. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy J Med Chem. 2021 Mar 11;64(5):2576-2607._x000D_ 6: Dragovich PS, Pillow TH, Blake RA, Sadowsky JD, Adaligil E, Adhikari P, Bhakta S, Blaquiere N, Chen J, Dela Cruz-Chuh J, Gascoigne KE, Hartman SJ, He M, Kaufman S, Kleinheinz T, Kozak KR, Liu L, Liu L, Liu Q, Lu Y, Meng F, Mulvihill MM, O'Donohue A, Rowntree RK, Staben LR, Staben ST, Wai J, Wang J, Wei B, Wilson C, Xin J, Xu Z, Yao H, Zhang D, Zhang H, Zhou H, Zhu X. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties J Med Chem. 2021 Mar 11;64(5):2534-2575._x000D_ 7: Alexanian M, Padmanabhan A, Nishino T, Travers JG, Ye L, Lee CY, Sadagopan N, Huang Y, Pelonero A, Auclair K, Zhu A, Teran BG, Flanigan W, Kim CK, Lumbao-Conradson K, Costa M, Jain R, Charo I, Haldar SM, Pollard KS, Vagnozzi RJ, McKinsey TA, Przytycki PF, Srivastava D. Chromatin Remodeling Drives Immune-Fibroblast Crosstalk in Heart Failure Pathogenesis bioRxiv [Preprint]. 2023 Jan 7:2023.01.06.522937._x000D_ 8: Wellinger LC, Hogg SJ, Newman DM, Friess T, Geiss D, Michie J, Ramsbottom KM, Bacac M, Fauti T, Marbach D, Jarassier L, Thienger P, Paehler A, Cluse LA, Kearney CJ, Vervoort SJ, Trapani JA, Oliaro J, Shortt J, Ruefli-Brasse A, Rohle D, Johnstone RW. BET Inhibition Enhances TNF-Mediated Antitumor Immunity Cancer Immunol Res. 2022 Jan;10(1):87-107._x000D_ 9: Yu H, Shi T, Yao L, Xu D, Ding Y, Xia Q, Liu W, Wang X. Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion Cell Mol Immunol. 2023 Aug;20(8):867-880._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/30266108">10: Ni JM, Ni AP. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy Chin Med Sci J. 2018 Sep 20;33(3):174-182. </a>_x000D_ _x000D_ <strong>Products Related to BRD4 Antibody Polyclonal can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>